 |
| Research |
On This Page
 |
Introduction |
|
Products |
|
Services |
|
Product Specifications |
|
|
Introduction
Since 1978, Stanford Medical School Blood Center has been providing tailored blood products and samples, as well as clinical trial services, for its own staff of primary investigators and researchers in Stanford University and the biotech community.
We offer a variety of products and services that can assist you and your company with research activities. Services we offer include:
- Blood products for in-vitro use
- Blood products for in-vivo use (clinical trials)
- Clinical laboratory testing services
- Research donor selection and recruitment
Products for In-Vitro Use:
The Stanford Blood Center provides blood products for in-vitro investigational use. Tubes or whole units of blood may be collected from individuals selected by the researcher or recruited by the Blood Center. Products collected for in-vitro investigational use are not routinely tested for infectious disease markers, although donor pre-screening can be arranged. Because products for in-vitro use do not meet the same safety criteria as blood products for transfusion, these components must not be used for infusion or for manufacturing into infusible products. Please contact our Research Coordinator at (650) 724-2997 for more information.
Products for In-Vivo Use (Clinical Trials):
The Stanford Medical School Blood Center collects blood products for investigational in-vivo use. Products may be collected from patients for re-infusion into the same patient (autologous donors), from relatives of patients (designated donors) or from normal healthy donors (allogeneic donors). IRB approval is required for all trials involving investigational in-vivo use of blood products. For information about our clinical trials program, please contact our Clinical Trials Coordinator at (650) 723-2597.
Products
(For full product descriptions, see Product Specifications)
Leukocytes (White Blood Cells)
Description
- Buffy coat from whole blood
- Lymphocytes, collected by automated technology
- Hematopoietic Progenitor Cells (stem cells)
Plasma
Description
- Plasma, frozen or liquid 200 mL
- 400 mL (single donor)
- Plasma, cryoreduced, frozen or liquid 200 mL
Platelets
Description
- Platelets, collected by automated technology
- Platelets with concurrent plasma, collected by automated technology
- Salvage platelets, collected by automated technology (outdated or do not meet specs)
Red Blood Cells
Description
- Red blood cells, collected by automated technology
- White cell reduced red blood cells (Leukoreduced RBC)
- Red blood cells (anticoagulants: CPD, CPDA1)
- Plasma Reduced (minimal residual plasma)
- Salvage Red blood cells (outdated or do not meet specs)
Whole Blood
Description
- Unseparated
- Unit of blood, non-anticoagulated (clotted), unseparated
- Unit of blood, non-anticoagulated (clotted),
separated
(minimum of 24 hr post-collection)
- Salvage Whole Blood (outdated or do not meet specs)
Tubes only
Description
- Tubes* (various anticoagulants or non-anticoagulanted)
- Tubes, venipuncture for collection of
*See Product Specification s for volume and types of tube
Services
Donor Recruiting and Selection
Description
- Recruit and schedule donors
Product Customization
Description
- Aliquot (set of 4)
- Irradiation
- Modification of collection procedure
- Product manipulation
- Selection by ABO and/or CMV, per product
- Selection by Aspirin use
- Selection by demographic information (age, gender, ethnicity), per product.
- Special requests (e.g. red cell antigen, HLA type, repeat donor, matched tubes, etc.) ,
Clinical Laboratory Tests (Donor or product, unless otherwise specified)
Description
- ABO/Rh
- CBC, automated, with 3 part differential
- CMV
- Hemoglobin S
- Hepatitis panel ( incl. HBsAg, aHBc, aHCV)
- Infectious disease panel (incl. HBsAg, aHBc, aHCV, aHIV-1/2, HIV-1 (p24) Ag, aHTLV-I/II, STS)
- Infectious disease panel with counseling services
- Confirmatory testing (if infectious disease screen is positive):
- Hepatitis B Neutralization
- Hepatitis C RIBA 3.0
- HIV-1 Western Blot
- HIV-2 ELISA
- HIV-2 Western Blot
- HIV-1 Antigen Neutralization
- HTLV-I/II Western Blot
- TPPA (Syphilis)
- Platelet antibody screen and ID
- Platelet crossmatch
- RBC Antigen Screen
- White blood cell count, final product, flow cytometry
HLA Testing
Description
- DNA extraction and storage
- Serology Technique
- HLA A, B antibody phenotype
- HLA antibody screen
- HLA antibody screen, rapid
- HLA autocontrol
- HLA B lymphocyte crossmatch
- HLA crossmatch sample management
- Molecular (DNA) Technique
- HLA A, AB typing
- HLA C locus (med-high resolution)
- HLA cell isolation, Dynabead
- HLA DR typing
- HLA DR typing, high resolution
- HLA DR typing, high resolution (SSP) or Non-Exon 2
- HLA STR testing
Flow Cytometry
Description
- Flow cytometry analysis
- Flow cytometry ‘Vantage' analysis
- Flow cytometry sorting
- HLA T-cell flow crossmatch
- HLA T-lymphocyte crossmatch
- Subsets
- Populations
- Subsets & populations (single sample)
- Other marker (1 only)
- Other markers (2 or more)
Miscellaneous Fees
Description
- Apheresis set-up
- Central Line Apheresis Procedure
- Clinical Trial set up
- Consent or contract variation development
- Extended hours (services scheduled before or after blood center posted hours), charged per hour
- Physician consultation
- STAT collection, apheresis (<24 hours notice)
Product Specifications
Legend
| HCT | Hematocrit, or percent red blood cells |
| Lymph | Lymphocytes, both mature and variant (atypical) |
| Mid | Monocytes, eosinophils, basophils, and other large mononuclear cells such as blasts, metamyelocytes, myelocytes, etc. |
| Gran | Neutrophils |
Anticoagulants and Additive Solutions
ACD-A Anticoagulant Citrate Dextrose solution USP (ACD) Formula A
- Dextrose (monohydrate)
- Sodium Citrate (dihydrate)
- Citric Acid (anhydrous)
AS-3 Additive Solution Formula 3 (100mL added to ACD-A Red Blood Cells collected by apheresis)
Each 100 mL contains:
- Dextrose (monohydrate), USP 1.10 g
- Sodium Citrate (dihydrate), USP 0.588 g
- Sodium Chloride, USP 0.410 g
- Monobasic Sodium Phosphate (monohydrate), USP 0.276 g
- Citric Acid (monohydrate), USP 0.042 g
- Adenine 0.030 g
CPD Anticoagulant Citrate Phosphate Dextrose USP
- Sodium Citrate (dihydrate) 26.3 g/L
- Dextrose (monohydrate) 25.5 g/L
- Citric Acid (anhydrous) 3.27 g/L
- Monobasic Sodium Phosphate (monohydrate) 2.22 g/L
AS-1 Adsol® additive formula (added to CPD Red Blood Cells)
- Sodium Citrate (dihydrate) 26.3 g/L
- Dextrose (monohydrate) 25.5 g/L
- Citric Acid (anhydrous) 3.27 g/L
- Monobasic Sodium Phosphate (monohydrate) 2.22 g/L
- Sodium Chloride
- Mannitol
- Adenine
CPDA-1 Anticoagulant Citrate Phosphate Dextrose Adenine Solution USP
- Dextrose (monohydrate) 31.9 g/L
- Sodium Citrate (dihydrate) 26.3 g/L
- Citric Acid (anhydrous) 3.27 g/L
- Monobasic Sodium Phosphate (monohydrate) 2.22 g/L
- Adenine 0.275 g/L
(In order of Research Products and Services tables)
Buffy Coat from whole blood
White blood cell concentrate prepared from a single unit of whole blood by centrifugation. Product contains red blood cells and plasma, and negligible amount of anticoagulant (CPD or CPDA-1). Store at 20-24C up to 24 hours.
Mean |
Range |
||
Min. |
Max |
||
| Vol (mL) | 30.5 |
23 |
38 |
| WBC thsn/mm3 | 49.8 |
21 |
94 |
| WBC (e9) | 1.5 |
0.6 |
2.7 |
| Hct % | 36.8 |
15.2 |
65.7 |
| % Gran | 47.7 |
28.7 |
67.7 |
| % Lymph | 35.6 |
21.7 |
59.1 |
| % Mono | 10.4 |
4.9 |
18.7 |
Lymphocytes, pheresis
Mononuclear cells collected from a single donor by a centrifugation apheresis technique. Cells are suspended in plasma with ACD-A anticoagulant added. Product is stored at room temperature (20 - 24C) for up to 24 hours.
| Median | Range | ||
| minimum | maximum | ||
| WBC thsn/mm3 | 77.6 | 50.4 | 127.7 |
| HCT % | 5.8 | 2.2 | 11.8 |
| Vol (mL) | 132 | 100 | 184 |
| Total WBC (e9) | 10.2 | 5.0 | 23.5 |
| %lymph | 73.2 | 37.4 | 78.9 |
| %mid | 15.2 | 12.2 | 20.2 |
| %gran | 12.3 | 8.5 | 46.5 |
| Lymph thsn/mm3 | 53.0 | 36.7 | 69.0 |
| Total Lymph (e9) | 7.0 | 3.7 | 12.7 |
| Mid thsn/mm3 | 11.3 | 6.5 | 25.8 |
| Total Mid (e9) | 1.5 | 0.7 | 4.7 |
| Gran thsn/mm3 | 7.7 | 5.2 | 53.7 |
| Total Gran (e9) | 1.0 | 0.5 | 9.9 |
Frozen plasma (FP)
Plasma separated from whole blood by centrifugation (200 mL product, anticoagulant CPD or CPDA-1) or collected by a centrifugation apheresis technique (400 mL product, anticoagulant ACD-A). Frozen at -18C within 8 hours of collection (6 hours for ACD-A plasma), FFP contains plasma proteins including all coagulation factors.
| Volume | ~ 200 or 400 mL |
| Fibrinogen | 2-4 mg/mL |
| Coagulation Factors | 1 IU/mL |
| Storage, frozen | < -18C, 12 months |
| Storage, thawed | 1-6C, 24 hours |
Recovered plasma, frozen
Plasma separated from whole blood by centrifugation and frozen at -18C between 8 and 24 hours of whole blood collection. Contains Factor VIII:C as well as other labile and stable coagulation factors, anticoagulant CPD or CPDA-1.
| Volume | ~200 mL |
| Factor VIII:C | ~150 IU |
| Storage, frozen | < -18C, 12 months |
| Storage, thawed | 1-6C, 24 hours |
Plasma, liquid
Fluid portion of whole blood separated by centrifugation from whole blood unit (200 mL product, anticoagulant CPD or CPDA-1) or by apheresis (400 mL product, anticoagulant ACD-A). Contains plasma proteins including stable coagulation factors.
| Volume | 200 or 400 mL |
| Fibrinogen | ~2-4 mg/mL |
| Stable coagulation factors only* | 1 IU/mL |
| Storage | 1-6C, 24 hours |
*Not a source of Factors V or VIII
Cryoreduced plasma products
Plasma remaining after removal of cryoprecipitated AHF. Significantly reduced clotting factors and fibrinogen.
Platelets, pheresis
Platelets collected from a single donor by a centrifugation apheresis technique. Each product contains platelets suspended in plasma and anticoagulant ACD-A.
| Volume | 200-300 mL |
| Platelets | > 3.0 x 10 11 |
| Storage | 20-24C, continuous gentle agitation, 5 days |
Concurrent plasma
Plasma up to 200 mL collected from a single donor concurrently with an apheresis platelet collection. See Fresh Frozen Plasma and Plasma, liquid.
Leukoreduced platelets, pheresis
Unless specified, platelets, pheresis undergo white blood cell reduction during the automated collection process, resulting in residual WBC < 5.0 x 10 6 .
Additive Red Blood Cells
AS-5 red blood cells are prepared by centrifuging whole blood to remove as much plasma as possible, and replacing the plasma with Adsol (see Legend ). Cells have lower viscosity than CPD or CPDA-1 Red blood Cells, and flow in a manner more comparable to that of whole blood. AS-3 red blood cells are collected by apheresis at the end of a platelet or platelet-plasma procedure.
AS-5 (WB)
| Volume | ~300 mL |
| HCT | 55-65% |
| Storage | 1 - 6C, 42 days |
AS-3 (Aph)
| Volume | ~350 mL |
| Absolute RBC volume | 154 - 207 mL |
| Storage | 1 - 6C, 42 days |
CPD or CPDA-1 Red Blood Cells
Prepared from whole blood collected into CPD or CPDA-1 anticoagulant-preservative (see Legend ), and separated from the plasma by centrifugation or sedimentation.
| Volume | ~230 mL |
| HCT | 65-80% |
| Storage, CPD | 1 - 6C, 21 days |
| Storage, CPDA-1 | 1-6C, 35 days |
Red Blood Cells, Leukoreduced
Prepared by filtering red blood cells with Pall BPF4 Leukocyte Filter. Filtering may be done within 5 days of draw. Residual leukocytes in filtered red blood cells are <5 x 10 6 with retention of 85% of the original component.
Red blood cells, dry packed
Red blood cells, or leukoreduced red blood cells derived from 450 mL of whole blood, further centrifuged to achieve final HCT of >85%. Not available in AS-1 anticoagulant-preservative.
Whole blood
| Volume | 500 mL (±10%) |
| HCT | > 34% |
| Storage, CPD | 1 - 6C, 21 days |
| Storage, CPDA-1 | 1-6C, 35 days |
Whole blood, fresh
Whole blood released within 4 hours of collection, untested, or within 24 hours of collection, tested.
Tubes
Red top (clot), 7mL
There is no additive or anticoagulant added to this tube.
Used for specific procedures requiring serum.
Purple (lavender) top (EDTA-liquid), 7 mL
Contains 0.07 mL of 15% buffered solution or the calculated equivalent of 10.5 mg EDTA (K 3 ). EDTA or ethylenediamineteteracetic acid chelates calcium to prevent clotting.
Used primarily for hematology and specific chemistry procedures requiring plasma or whole blood. EDTA whole blood samples are superior for flow cytometry studies because the formation of artifacts is prevented, even after prolonged standing.
Purple (lavender) top (EDTA-liquid), 5 mL
Contains 0.050 mL of 15% buffered solution or the calculated equivalent of 7.5 mg EDTA (K 3 ). EDTA or ethylenediamineteteracetic acid chelates calcium to prevent clotting.
Used primarily for hematology and specific chemistry procedures requiring plasma or whole blood. EDTA whole blood samples are superior for flow cytometry studies because the formation of artifacts is prevented, even after prolonged standing.
Yellow top (ACDA-liquid), 8.5 mL
Contains 1.50 mL of anticoagulant Acid Citrate Dextrose Solution (A). ACD-A contains nutrients to help maintain the whole blood for several weeks.
Used primarily for specific immunohematology and histocompatibility procedures requiring preservation of whole blood.
Green top (Heparin), 10 mL
Contains 143 USP Units of Sodium Heparin. Heparin inhibits thrombin to prevent clotting.
Used for chemistry and selective hematology determinations. This anticoagulant is best for prevention of hemolysis and for osmotic fragility tests.
